KCNT1 Epilepsy Foundation News & Updates
Stay updated with the latest news on KCNT1 epilepsy, including genetic research, drug advancements, patient stories, advocacy efforts, and support for parents.
Roman’s Reason: Ride for Roman Hunt and all those living with KCNT1
Roman and his family are featured on PA ahead of the big Million Dollar Bike Ride!
2023 Quarter 1 Newsletter
Parents can keep up-to-date on some of the top news and studies.
Raising Awareness for KCNT1 Down Under
One of our KCNT1 warriors continues to spread the word about KCNT1 and the need for new treatments and funding for research.
Raising Awareness in the UK
Our parent ambassador, Catherine Holliday, is doing a great job creating awareness for KCNT1. Her family has been featured by numerous media outlets after Action Medical funded a drug repurposing screening in search for KCNT1 inhibitors. We hope to identify a top candidate from the screening to take to clinical trials soon.
Arpin Strong Selects KCNT1 Foundation
We are grateful for the Arpin International Group and Arpin Strong for selecting our charity to support for the month of March. Arpin’s history of giving back to the community is commendable and we are honored to have been selected and supported by all the employees. The entire KCNT1 community says thank you!
AI Based Drug Discovery & Development – Not a long shot anymore
World Pharma Today’s interview by Dhaval Patel, Executive Vice President and Chief Scientific Officer of UCB, a global biopharmaceutical company focused on the discovery and development of novel drugs (including KCNT1) and solutions that have the potential to transform people’s lives. We also go in-depth on how UCB has advanced the field of drug discovery through technological partnerships.
Pick sunflowers for a donation at Freeling
Thanks to the Barns of Freeling for hosting a fundraiser. Over 1,000 people came out to water and pick sunflowers and many made a donation to the KCNT1 Epilepsy Foundation. Thank you to 7News!
Collaboration between UCB and Praxis for a KCNT1 Small Molecule
UCB, a global biopharmaceutical company (EURONEXT BRUSSELS: UCB), and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies.
ASO Therapies Show Promise for KCNT1
Treatment of KCNT1 mutant mouse models show improvements in behavior and reduced seizures.
Welcome Stanford GC Interns
We are grateful to have the support of three interns this summer: Jacqueline Fung, Michaela Taylor, Astrid Torres!
Celebrating Men in Rare Epilepsies Making a Difference
Co-founder, Justin West participates in a panel of rare dads who are working to make a difference.
KCNT1 Epilepsy Foundation Visits London
Foundation Executive Director visits labs to learn about the KCNT1 cell models they are developing.